Case Reports

Occult cancer: suspected breast and BRCA gene mutations


 

Currently, the best means of managing and preventing breast cancer is through early detection and identification of women who are at significantly increased risk for the disease. Those who are at increased risk are candidates for genetic testing involving the BRCA1 and BRCA2 genes. However, those who present with an occult cancer present a significant challenge in regard to etiology, which can have an impact on decisions about cancer risk management. We report here on two cases demonstrating an association between occult cancer, with suspected breast primary, and the presence of a BRCA gene mutation. These cases draw attention to the fact that occurrences of occult cancer, in particular those with a suspected breast primary, warrant consideration of genetic testing for possible mutations in the BRCA1 and BRCA2 genes. This is especially important as identification of a mutation will impact secondary cancer risk and medical management decisions.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Genetic alterations affect everolimus benefit in breast cancer
MDedge Hematology and Oncology
Racial discrepancy in breast cancer survival examined
MDedge Hematology and Oncology
Stem cell mutations in breast cancer may confer metastatic risk
MDedge Hematology and Oncology
Guidelines issued on radiation-induced heart disease
MDedge Hematology and Oncology
Age does not impact survival in HER2-positive breast cancer
MDedge Hematology and Oncology
Long-term CCB therapy linked to higher breast cancer risk
MDedge Hematology and Oncology
Bernard Fisher at 95
MDedge Hematology and Oncology
Lymph node status predicted 10-year mortality in BRCA1 mutation carriers with small, stage I-III breast cancers
MDedge Hematology and Oncology
Long-term amenorrhea risk no higher for premenopausal breast cancer patients with BRCA mutations
MDedge Hematology and Oncology
Adjuvant ibandronate adds no benefit in early stage, node-positive breast cancer
MDedge Hematology and Oncology